Supplementswell supported · human dataDiscovery of the day
In people with prediabetes or type 2 diabetes, CoQ10 supplementation significantly reduced triglycerides, fasting blood sugar, HbA1c, insulin resistance and the inflammation marker C-reactive protein, and raised HDL, across 20 randomised trials; total cholesterol, LDL and blood pressure did not change.
- Study design
- Meta-analysis
- Journal
- BMC Pharmacol Toxicol
- Evidence
- well supported
What it shows: Encouraging but not the final word: results pooled from 20 trials in people with prediabetes or type 2 diabetes, and the trials disagreed with each other on how big the benefits were. The authors want longer studies across a range of doses before firm conclusions.Meta-analysis · BMC Pharmacol Toxicol
The effect of CoQ10 supplementation on cardiovascular risk factors in patients with prediabetes and type 2 diabetes mellitus: a grade-assessed systematic review and dose-response meta-analysis. BMC Pharmacol Toxicol 2026Read the study →